Clinical trial · Observational
Isolated Thoracic Perfusion (ITP-F) for MPM
Isolated Thoracic Perfusion With Hemofiltration (ITP-F) for Pretreated and Progressive Malignant Pleural Mesothelioma
NCT02467426CI-TRIAL-00018221completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study of isolated thoracic perfusion with subsequent hemofiltration to lower the concentration of the cytotoxic drugs as a locoregional therapeutic strategy in malignant pleural mesothelioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mesothelioma | Malignant Mesothelioma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Chemotherapy
- description
- intraarterial chemotherapy with cisplatin and mitoxantrone
- interventionNames
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Survival
- timeFrame
- one year survival
- description
- Kaplan-Maier Plot
Secondary outcomes (1)
- measure
- Toxicity
- timeFrame
- 4 weeks after therapy
- description
- Toxicity was measured by Common Toxicity Criteria Vers. 2.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * History of pre-treated Malignant Pleural Mesothelioma, Progress after Staging Exclusion Criteria: * Drug abuse, distant metastases, no bone marrow function
References
Publications (0)
Data not yet available
No reference posted for this study.